Gli Stati Uniti. La Drug Administration approva l’uso di emergenza del primo farmaco antivirale orale contro il Covid-19

Agenzia di stampa Xinhua, Washington, Dicembre 22 (Il giornalista Tan Jingjing) Il 22 °, gli Stati Uniti. La Food and Drug Administration ha approvato il primo farmaco orale che può essere utilizzato urgentemente per trattare le infezioni da COVID-19 negli adulti e nei bambini di età compresa tra 12 e anziani che hanno malattie da COVID-19 da lievi a moderate, così come quelli a più alto rischio di malattie gravi.

The US Drug Administration said in a statement that the oral COVID-19 antiviral medicine by Pfizer is called Paxlovid and consists of two antiviral drugs. Patients must take it as soon as possible after the diagnosis of the new crown, and start taking it within 5 days after the appearance of the new crown symptoms, and the continuous use time cannot exceed 5 giorni.

The statement said that after evaluating all available scientific evidence, the US Drug Administration believes that Paxlovid may be effective in the treatment of patients with mild to moderate COVID-19, and its known and potential benefits exceed its known and potential risks. Common side effects of this drug may include impaired taste, diarrea, ipertensione, and muscle aches.

Cavazzoni, director of the Center for Drug Evaluation and Research of the US Drug Administration, said that with the emergence of new mutant strains, the prevention and control of the COVID-19 epidemic has entered a critical stage, and the emergency authorization to use this oral drug provides a new tool to combat the COVID-19.

Fonte: Agenzia di stampa Xinhua